Medicine and Dentistry
Adalimumab
9%
Anti-Citrullinated Protein Antibody
5%
Arthritis
7%
Betamethasone
8%
Cohort Analysis
6%
Cyclosporine
10%
DAS28
9%
Disease Activity
17%
Disease Modifying Antirheumatic Drug
14%
Disease-Modifying Antirheumatic Drug
7%
Eosinophilia
8%
Etanercept
5%
Glucocorticoid
11%
Immunoglobulin M
5%
Inflammatory Arthritis
78%
Infliximab
7%
Magnetic Resonance Imaging
23%
Methotrexate
18%
Osteolysis
6%
Placebo
6%
Primary Health Care
5%
Psoriatic Arthritis
7%
Randomized Controlled Trial
9%
Rheumatoid Arthritis
78%
Rheumatoid Factor
5%
Spontaneous Remission
7%
Synovitis
5%
TNF Inhibitor
14%
Tocilizumab
8%
Treatment Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
15%
Arthritis
9%
Biological Marker
8%
Biological Product
6%
Ciclosporin
6%
Cohort Study
9%
Disease
5%
Disease Activity
15%
Disease Activity Score
10%
Disease Modifying Antirheumatic Drug
12%
Glucocorticoid
10%
Inflammatory Arthritis
68%
Infliximab
8%
Methotrexate
17%
Monotherapy
5%
Placebo
6%
Randomized Controlled Trial
6%
Remission
27%
Rheumatoid Arthritis
68%
Synovitis
5%
Tocilizumab
5%
Tumor Necrosis Factor Inhibitor
12%
Immunology and Microbiology
Adalimumab
15%
Anti-Citrullinated Protein Antibody
14%
Arthritis
7%
Autoimmune Disease
5%
Blood Level
5%
C-Reactive Protein
6%
Comorbidity
7%
Disease-Modifying Antirheumatic Drug
12%
Galectin 3
6%
Glucocorticoid
6%
Immunoglobulin M
8%
Immunology
12%
Inflammatory Arthritis
100%
Infliximab
9%
Magnetic Resonance Imaging
17%
Methotrexate
13%
Osteitis
5%
Rheumatoid Factor
9%
Synovitis
15%
TNF Inhibitor
7%
Tocilizumab
5%
